Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research

Part of paid clinical trials in Houston, Texas.

Sponsor
Oculis
Study ID
NCT07623668
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Optic Neuritis

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Privosegtor — DRUG
    Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days
  • Methylprednisolone — DRUG
    Methylprednisolone 1 g/day IV for 5 treatment days
  • Placebo — OTHER
    0.9% sodium chloride (NaCl) solution IV for 5 treatment days

Study Details

The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).

Key Dates

Start date
May 28, 2026
Status verified
May 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
210 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Privosegtor
  • Placebo Comparator: Placebo

Primary Outcome Measure

Proportion of participants achieving at least 15-letter gain from baseline in low contrast visual acuity (LCVA). [ Time Frame: 3 months ]

Central Contacts

Locations (1)

FacilityCityStateZIP
Neuro-Eye Clinical TrialsHoustonTexas77074

Find similar trials in Houston, TX

By research site
Neuro-Eye Clinical Trials· Houston, TX

Related Studies